Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.
A Phase 1 clinical trial led by researchers at the University of Maryland School of Medicine has demonstrated that a novel ...
The approval is based on a multi-center, randomized, open-label, controlled, Phase 3 KL166-III-06 study that evaluates the efficacy and safety profile of trastuzumab botidotin versus T-DM1 in patients ...
Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio: Ingelheim, Germany Friday, October 17, 2025, 11:00 Hrs [IST] Boehringer Ingelheim ...
NEW YORK – Akari Therapeutics on Wednesday said it hopes to raise $2.5 million by selling 3,125,000 American depositary shares (ADS) in a registered direct offering.
Enhertu Benefit in HER2-Low Breast Cancer That's Also HR-Negative Supported by Longer Follow-Up Data
Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.
Pokemon Legends: Z-A is available now, and you can bundle the new game with the Nintendo Switch 2 to save some cash.
French antibody specialist Adcytherix has added a 105 million euro ($122 million) series A to its coffers, money the ...
BBC tennis correspondent Russell Fuller looks at how Emma Raducanu's 2025 season went - and what the future could hold.
The Apple iPad completely revolutionized the tablet scene when it first hit the market in 2010. Its bigger screen combined with beloved iPhone features from iOS combined to offer a new way for users ...
The Food and Drug Administration has granted Breakthrough Therapy designation to CD388 for seasonal influenza prevention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback